Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Broad Label Gives Tesaro's Niraparib A Head Start In Ovarian Cancer

OvarianCancer_1200x675

Related Content

AstraZeneca Mulls Broad Ovarian Cancer Maintenance Approval For Lynparza

Mar 15 2017

Tesaro Doubles On Super NOVA Data, Lifts PARP Competitors

Jun 30 2016

Related Companies

Tesaro, Inc.

AstraZeneca PLC

Clovis Oncology, Inc.

AbbVie Inc.

Roche Holding AG

Merck & Co., Inc.

Additional Topics

Approvals Clinical Trials Regulation Research & Development Cancer BioPharmaceutical

More from New Products

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window